Zilola Avazovna Olimova

2 ta ish

Tashkent Pediatric Medical Institute

1. Is early inclusion of neratinib with HER blockers possible in the treatment of stage 4 HER2 positive cancer?

   Zilola Avazovna Olimova

   MaqolaOAOchiq kirishHER2/EGFR in Cancer ResearchJournal of Clinical Oncology20240 iqtibos

   ABIABI:AkademIndex/2024.article.007521

2. Abstract 2510: Comprehensive genomic profiling drives precision oncology and expands accessibility to targeted therapies in Uzbek populations

   Zilola Avazovna Olimova, Gowhar Shafi, D. Farrukh +10

   MaqolaCancer Genomics and DiagnosticsCancer Research20260 iqtibos

   ABIABI:AkademIndex/2026.article.010172